Medicenna in the spotlight (part V)

Assessing additional biomarker data

Following up on our previous post — last week, Medicenna (MDNA) released additional details on the biomarker data that was reported last month. The data, albeit early, is showing activity at low doses. With dosing expected to go significantly higher, MDNA has potential to outperform the other IL-2 players in clinic. 

Understanding Dosing & IL-2 Content
MD…